Abstract Number: LPB0049
Meeting: ISTH 2021 Congress
Background: Essential Thrombocythemia (ET) is a myeloproliferative neoplasm characterized by an overproduction of platelets by the bone marrow. Furthermore, it can cause severe complications such as stroke or venous thromboembolism. Despite the intrinsic connection between ET and cardiovascular events, there is a paucity of data on hospitalization risk for cardiovascular events in patients with ET.
Aims: Our objective was to identify prevalent comorbidities among patients with ET who were hospitalized for cardiovascular disease.
Methods: We performed a retrospective analysis of the National Inpatient Sample (NIS) database from 2016 to 2017. Patients included were at least 18 years of age and had an ICD-10 code for ET. To identify cardiovascular outcomes, an ICD-10 code for Venous Thromboembolism, Stroke, Acute Coronary Syndrome, or Major Adverse Limb Events must be present in the top three discharge diagnoses. We used descriptive statistics to find common chronic comorbidities and performed binary logistic regression to identify prevalent risk factors for hospitalizations due to cardiovascular disease. All statistical analyses were performed in SPSS.
Results: We identified a total of 234,225 (weighted) hospitalizations of patients with ET. Patients had a mean age of 59.72 years of age (SD = 18.679), and they were predominantly female (57%). Cardiovascular outcomes were present in 18,955 hospitalizations (8.10%). prevalence for cardiovascular outcomes among patients with ET were: valvular disease (odds ratio, 1.33 [95% CI, 1.23-1.43]; P<0.0001), peripheral vascular disease (odds ratio, 1.97 [95% CI, 1.87-2.07]; P<0.0001), paralysis (odds ratio, 1.63 [95% CI, 1.54-1.73]; P<0.0001), renal failure (odds ratio, 1.06 [95% CI, 1.01-1.11]; P=0.013), hypertension (odds ratio, 1.36 [95% CI, 1.32-1.41]; P<0.0001), and cancer (odds ratio, 1.06 [95% CI, 1.01-1.12]; P=0.020).
Conclusions: The most prevalent risk factors of hospitalizations for cardiovascular events among patients with ET include valvular disease, peripheral vascular disease, and paralysis. Additional evaluation should be done to consider optimization of prevention strategies for cardiovascular outcomes.
To cite this abstract in AMA style:Tafur G, Saadaldin H, Velazquez F, Marinescu E, Tafur A. Cardiovascular Outcomes in Patients with Essential Thrombocythemia: Analysis of the National Inpatient Sample (NIS) [abstract]. Res Pract Thromb Haemost. 2021; 5 (Suppl 1). https://abstracts.isth.org/abstract/cardiovascular-outcomes-in-patients-with-essential-thrombocythemia-analysis-of-the-national-inpatient-sample-nis/. Accessed September 24, 2021.
« Back to ISTH 2021 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/cardiovascular-outcomes-in-patients-with-essential-thrombocythemia-analysis-of-the-national-inpatient-sample-nis/